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Abstract
Centronuclear myopathy (CNM) is an inherited neuromuscular disorder characterised by clinical features of a congenital
myopathy and centrally placed nuclei on muscle biopsy.
The incidence of X-linked myotubular myopathy is estimated at 2/100000 male births but epidemiological data for other forms
are not currently available.
The clinical picture is highly variable. The X-linked form usually gives rise to a severe phenotype in males presenting at birth with
marked weakness and hypotonia, external ophthalmoplegia and respiratory failure. Signs of antenatal onset comprise reduced
foetal movements, polyhydramnios and thinning of the ribs on chest radiographs; birth asphyxia may be the present. Affected
infants are often macrosomic, with length above the 90th centile and large head circumference. Testes are frequently
undescended. Both autosomal-recessive (AR) and autosomal-dominant (AD) forms differ from the X-linked form regarding age
at onset, severity, clinical characteristics and prognosis. In general, AD forms have a later onset and milder course than the X-
linked form, and the AR form is intermediate in both respects.
Mutations in the myotubularin (MTM1) gene on chromosome Xq28 have been identified in the majority of patients with the X-
linked recessive form, whilst AD and AR forms have been associated with mutations in the dynamin 2 (DNM2) gene on
chromosome 19p13.2 and the amphiphysin 2 (BIN1) gene on chromosome 2q14, respectively. Single cases with features of CNM
have been associated with mutations in the skeletal muscle ryanodine receptor (RYR1) and the hJUMPY (MTMR14) genes.
Diagnosis is based on typical histopathological findings on muscle biopsy in combination with suggestive clinical features; muscle
magnetic resonance imaging may complement clinical assessment and inform genetic testing in cases with equivocal features.
Genetic counselling should be offered to all patients and families in whom a diagnosis of CNM has been made.
The main differential diagnoses include congenital myotonic dystrophy and other conditions with severe neonatal hypotonia.
Management of CNM is mainly supportive, based on a multidisciplinary approach. Whereas the X-linked form due to MTM1
mutations is often fatal in infancy, dominant forms due to DNM2 mutations and some cases of the recessive BIN1-related form
appear to be associated with an overall more favourable prognosis.
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Disease name
Centronuclear (myotubular) myopathy
Definition
Centronuclear myopathy (CNM) is an inherited neu-
romuscular disorder defined by a) numerous centrally
placed nuclei on muscle biopsy and b) clinical features of
a congenital myopathy. Additional but inconsistent his-
topathological features comprise a surrounding central
zone either devoid of oxidative enzyme activity or with
oxidative enzyme accumulation, and, in patients with
mutations in the dynamin 2 (DNM2) gene, radial sarco-
plasmic strands surrounding the central area; signs of
necrosis or excessive regeneration are usually absent in all
forms of CNM.
Centronuclear myopathy exists in X-linked recessive
(OMIM 310400) [1], autosomal-dominant (OMIM
160150) and autosomal-recessive forms (OMIM
255200). The term myotubular myopathy [2], introduced
because of a similar appearance of affected fibres and foe-
tal myotubes, is still used by many for the X-linked form,
whilst centronuclear myopathy is a term used for both the
autosomal-dominant and recessive variants of the condi-
tion.
Epidemiology
Epidemiological data are only available for the congenital
myopathies as a group but not for specific conditions. The
incidence of all congenital myopathies (including central
core disease, multi-minicore disease, nemaline myopathy
and centronuclear myopathy) is estimated at around
0.06/1,000 live births, or one-tenth of all cases of neu-
romuscular disorders [3]. Regional studies in Northern
Ireland [4] and Western Sweden [5], suggest a prevalence
of 3.5 – 5.0/100,000 in a paediatric population. These
numbers are likely to be underestimates, as histopatho-
logical expression of specific genetic defects may be varia-
ble and often non-specific, particularly at a young age.
Based on unpublished observations (JL), the incidence of
molecularly confirmed myotubular myopathy in France is
estimated at 2/100,000 male births per year. Whilst data
regarding the overall incidence and prevalence of CNM
are not available, the condition clearly occurs less fre-
quently than central core disease and multi-minicore dis-
ease, the most common congenital myopathies, and
nemaline myopathy (HJ, personal observation).
Clinical description
Whilst creatine kinase (CK) is normal or only slightly ele-
vated in all forms of centronuclear (myotubular) myopa-
thy, the clinical picture is highly variable depending on
the causative mutation.
The X-linked form due to mutations in the myotubularin
(MTM1) gene has been clinically well characterised and
usually gives rise to a severe phenotype in males present-
ing at birth with marked weakness and hypotonia, exter-
nal ophthalmoplegia and respiratory failure (Figure 1) [6-
19]; a preceding family history of either male neonatal
deaths or miscarriages is common. Signs of antenatal
onset comprise reduced foetal movements, polyhydram-
nios and thinning of the ribs on chest radiographs [20,21]
and are only rarely observed in other congenital myopa-
thies. Birth asphyxia may be the presenting feature
[10,22]. Affected infants are often macrosomic, and
length above the 90th centile and large head circumference
may serve as a diagnostic clue [23,24]. Testes are fre-
quently undescended [25]. In the majority of cases the
course is fatal within the first months of life, but a propor-
tion of affected males may survive into their teens or
beyond [19,26,27]. Although a small proportion of boys
may be only mildly affected in the neonatal period and
thereafter [6,18,19,22,27-29], in the majority of long-
term survivors survival depends on a substantial degree of
medical intervention and often constant ventilation. A
range of medical complications in some long-term survi-
vors comprising pyloric stenosis and cavernous haeman-
giomas of the liver [26] has also been reported and may
indicate wider expression of the defective protein. Addi-
tional genital abnormalities have been described in
affected males with contiguous gene syndromes [30], and
is due to loss of the adjacent MAMLD1 (Cxorf6) gene [31].
The majority of carriers of the X-linked formare asympto-
matic but a few may show signs of mild muscle weakness
[10,32-34]. Presentation may be overt in females, espe-
cially if additional genetic abnormalities such as skewed
X-inactivation [34-39] or structural X-chromosomal
abnormalities are present [40]. Urinary incontinence, pri-
mary or secondary, may be an additional feature indicat-
ing smooth muscle involvement [33,37].
Male infant with X-linked centronuclear ("myotubular")  myopathy due to a mutation in the myotubularin (MTM1)  gene Figure 1
Male infant with X-linked centronuclear ("myotubu-
lar") myopathy due to a mutation in the myotubu-
larin (MTM1) gene. Note generalised hypotonia and 
myopathic facial appearance with elongated face and inverted 
V-shaped mouth. (Reproduced from MedLink®Neurology, 
with permission)Orphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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Both autosomal-recessive and autosomal-dominant
forms have been well documented and differ from the X-
linked form regarding age at onset, severity, clinical char-
acteristics and prognosis [18,41]. As a general rule, auto-
somal-dominant forms have a later onset and milder
course than the X-linked form, and the autosomal-reces-
sive form is intermediate in both respects, but these differ-
ences are quantitative rather than qualitative. Most reports
concerning autosomal-recessive and dominant forms of
CNM predate the molecular resolution of these condi-
tions and are likely to reflect genetically heterogeneous
conditions; however, the recent identification of the genes
implicated in subgroups of recessive and dominant CNM
offers the prospect of more precise genotype-phenotype
correlative studies in future.
The autosomal-recessive form [10,41-52] is characterised
by facial weakness including severe involvement of the
masticatory muscles [53], and ocular abnormalities such
as ptosis and external ophthalmoplegia. A recent French
series distinguishes early and late onset forms with or
without ophthalmoplegia; it remains to be seen if those
distinctions are reflective of underlying genetic heteroge-
neity [50]. Weakness is usually prominent proximally but
there may be additional distal weakness and wasting in
the lower limbs, and foot abnormalities are frequently
found [54]. Other skeletal deformities including high
arched palate and scoliosis are common [55]. Respiratory
involvement may be severe [52], and an associated cardi-
omyopathy has been documented in a few recurrent and
sporadic cases [44,56,57]. As in carriers of the X-linked
form, urinary incontinence may be an associated feature
[58]. In the absence of severe cardiorespiratory involve-
ment, the prognosis appears favourable. Whilst most of
the features of supposedly recessive cases of centronuclear
myopathy were reported in genetically unresolved cases,
identification of homozygous recessive mutations in the
amphiphysin 2 (BIN1) gene in 4 patients form 3 families
[59] allows initial genotype-phenotype correlations,
although, considering the small number of cases, the
range of clinical features associated with mutations in this
gene is likely to expand further in the future. Clinical fea-
tures in the patients identified to date suggested a pheno-
type of intermediate severity between the X-linked
recessive and the dominant forms, with onset from birth
to childhood and mild progressive proximal weakness but
no respiratory impairment severe enough to require ven-
tilatory assistance. Cardiac involvement was not present
in these patients but, notably, appears to be a feature in
the BIN1 knockout mouse [60].
Most patients with the autosomal-dominant form of
CNM are more mildly affected than those with the X-
linked or autosomal-recessive forms with a widely varia-
ble age of onset [18,61-75]. The distribution of weakness
is predominantly proximal with additional distal involve-
ment, external ophthalmoplegia and ptosis; in some
cases, prominent calf muscle hypertrophy may be an addi-
tional feature [50].
The autosomal-dominant form of CNM due to muta-
tions in the dynamin 2 (DNM2) gene may be of variable
severity depending on the part of the protein affected.
Dominant  DNM2  mutations affecting the dynamin 2
middle domain reported to date appear to be associated
with a mild clinical phenotype characterised by normal
early motor developmental milestones, onset in adoles-
cence and a slowly progressive course with loss of inde-
pendent ambulation uncommon before the 6th decade
[76-78]. In addition to signs of proximal weakness, exer-
cise-induced myalgia may be a presenting feature. Ocu-
lar involvement, particularly ptosis, is almost invariable
and distal muscle involvement, particularly in the lower
limb, may precede more proximal weakness; the latter
finding corresponds to a sequential pattern with early
involvement of the ankle plantarflexors, namely the
medial gastrocnemius, followed by signal changes in the
posterior and, eventually, anterior compartment of the
thighs [77,78]. Contractures other than those affecting
the Achilles tendon and/or long finger flexors are rare.
Electromyogram (EMG) and nerve conduction studies
may show mild signs of axonal peripheral nerve involve-
ment in addition to prominent myopathic changes
[77,79]. Whilst dominant mutations affecting the
dynamin 2 middle domain have been associated with a
mild phenotype of CNM, a more severe presentation
with neonatal onset has been recently attributed to het-
erozygous  de novo dominant mutations affecting the
pleckstrin homology (PH) domain of the dynamin 2
protein, a protein domain also altered in the CMTDIB
neuropathy [80,81]. Like other patients with CNM, these
had marked ocular involvement including ptosis and
ophthalmoparesis, and, despite a severe and early pres-
entation, gradually improved over time. However, whilst
cardiorespiratory function in DNM2-related CNM has
been normal in most reported cases those with early
onset may develop restrictive respiratory impairment
over time [81]. Electrophysiology showed exclusive
myopathic but no neuropathic changes.
Centronuclear myopathy due to a heterozygous de novo
dominant mutation in the skeletal muscle ryanodine
receptor (RYR1) gene has to date been reported in only
one case [82], with clinical features comprising extraocu-
lar involvement, generalized weakness, moderate bulbar
and respiratory impairment similar to multi-minicore dis-
ease (MmD), due to recessive mutations in the RYR1 gene
[83,84]. Although the frequency of RYR1 mutations in
CNM is currently uncertain, malignant hyperthermia sus-
ceptibility reported in a case of CNM in the premolecular
era [85] may indicate more widespread RYR1 involvement
in CNM.Orphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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Aetiology
Centronuclear (myotubular) myopathy exists in X-linked,
autosomal-recessive and autosomal-dominant forms.
The X-linked recessive form ("myotubular myopathy")
has been genetically well characterised. Following initial
linkage studies and assignment of a locus to chromosome
Xq28 [40,86-94] mutations in the myotubularin (MTM1)
gene have now been identified in more than 90% of
affected males [19,95-100]; molecular genetic analysis of
the MTM1 gene is now widely available as a routine diag-
nostic service [34,101,102]. Disease-causing sequence
changes include deletions/insertions, nonsense, missense
and splice mutations (approximately 25% each) [97,102].
Three substitutions account for 15% of all MTM1 muta-
tions; these are the splice mutation c.1261-10A>G
(intronic, upstream of exon 12) resulting in the insertion
of three amino acids FIQ at position 420 (7.3%), R241C
encoded by exon 9 (4%), and c.141-144 delAGAA result-
ing in a frameshift at amino acid 48 in exon 4 (4%) [28].
Other mutations have been reported in a few families or
are unique. MTM1 mutations are distributed throughout
the entire coding sequence, but localise most frequently
(in descending order) to exons 12, 4, 11, 8 and 9 [97-
99,102-107]. Maternal carrier state of MTM1 mutations is
estimated at 85% and is thus more common than statisti-
cally expected for a severe X-linked disease [97,102];
maternal mosaicism has been reported in a few families
[97,108,109] with important implications for genetic
counselling regarding future pregnancies.
Genotype-phenotype correlative studies have been diffi-
cult because many mutations are private to individual
families and clinical severity associated with specific
mutations may vary even within the same families; how-
ever, one large series demonstrated that, while most muta-
tions are associated with the severe phenotype, some non-
truncating mutations outside of the catalytic domain may
carry a more favourable prognosis [19,27,28,110].
Screening of the MTM1  gene should be considered in
females with suggestive clinical and histopathological fea-
tures; although usually asymptomatic or only mildly
affected, carriers may manifest severe symptoms in the
presence of skewed X-inactivation and/or structural alter-
ations involving the X-chromosome such as interstitial
deletions [34-40].
Myotubularin belongs to the large family of dual-specifi-
city phosphatases, playing a role in the epigenetic regula-
tion of signalling pathways involved in growth and
differentiation; mutations in some human myotubularin
homologues have been associated with two specific forms
of peripheral neuropathies of the Charcot-Marie-Tooth
(CMT) type, CMT 4B1 [111,112] and CMT 4B2 [113,114].
A specific function has been proposed for myotubularin
in dephosphorylating phosphatidylinositol 3-phosphate
[PtdIns3P] and PtdIns(3,5)P. These two phospholipids
are second messengers with a crucial role in membrane
trafficking; by dephosphorylation of PtdIns(3,5)P2, myo-
tubularin also produces PtdIns5P, whose function is not
fully characterised [95,115-126]. In addition to the cata-
lytic site, myotubularins form homo- and heterodimers
and contain lipid and protein binding sites; these
domains include a GRAM-PH, a coiled-coil region and a
putative PDZ binding site. Concerning myotubularin, no
protein interactors have been characterised to date in skel-
etal muscle. The deleterious effect of specific MTM1 muta-
tions may be due to either destabilisation of the 3-D
structure or loss of enzymatic activity, although it is possi-
ble that a few mutations affect existing but not yet identi-
fied protein-protein interactions in muscle.
Observations in an MTM1-related mouse model [127]
suggest a role of myotubularin in muscle fibre mainte-
nance but not in myogenesis. A recent gene expression
profiling study in muscle harbouring MTM1 mutations
revealed upregulation of transcripts for cytoskeletal and
extracellular matrix proteins within or around atrophic
myofibres, indicating that remodelling of cytoskeletal and
extracellular architecture plays a role in the atrophy and
intracellular disorganization observed in X-linked myotu-
bular myopathy [128]. Prolonged expression but eventual
decrease of developmentally regulated proteins in muscle
from affected infants (see also paragraph on Diagnostic
methods below) suggests maturational delay rather than
complete developmental arrest in this condition.
Dominant forms of centronuclear myopathy have been
associated with mutations in two genes, the dynamin 2
(DNM2) gene on chromosome 19p13.2 [76] also impli-
cated in dominant intermediate (CMTDIB) [80] and
axonal (CMT2) [129,130] forms of Charcot-Marie-Tooth
disease, and the skeletal muscle ryanodine receptor
(RYR1)  gene on chromosome 19q13.1 in one isolated
case [82].
The DNM2 gene consists of 22 exons [80] and encodes a
large GTPase protein involved in actin cytoskeleton
assembly [131] and centrosome cohesion [132]. In addi-
tion, DNM2 is implicated in membrane trafficking from
the plasma membrane and Golgi, to allow the formation
and fission of budding vesicles [133]. It is of interest to
note that myotubularin, implicated in the X-linked form
of CNM, has also been implicated in membrane traffick-
ing and endocytosis, although its precise function remains
to be determined. Recent studies on cells transfected with
CNM-related DNM2 mutants suggest lack of localisation
to the centrosome and centrosome malfunction as a pos-
sible pathogenetic mechanism in DNM2-related CNM.Orphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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However, the impacts of mutations on allosteric enzy-
matic activity and membrane remodelling properties of
dynamin 2 remain to be investigated. Recurrent and de
novo DNM2 mutations were originally identified follow-
ing a positional candidate approach in 11 families with a
mild form of autosomal-dominant centronuclear myopa-
thy [76]. The most common mutation is a 1393C>T
change found in 6 unrelated families resulting in an
arginine to tryptophane substitution at position 465.
Dynamins are structurally complex proteins composed of
5 different domains; CNM-causing mutations identified
to date mainly localise to the middle domain involved in
protein self assembly and centrosome localisation [76],
whereas those associated with CMTDIB have been identi-
fied within the pleckstrin homology (PH) domain [80].
More recently, heterozygous de novo dominant  DNM2
mutations affecting the PH domain have also been identi-
fied in a more severe CNM phenotype without any early
peripheral nerve involvement and characterised by neona-
tal onset but gradual improvement over time [81]. The
potential overlap between myogenic and neurogenic find-
ings in families with mutations in this region is currently
being explored [77,79].
Features of centronuclear myopathy associated with the
skeletal muscle ryanodine receptor (RYR1) gene have to
date only been reported in one single case with a de novo
dominant mutation resulting in a serine to leucine substi-
tution at position 4112 [82]; the RYR1 gene had been con-
sidered as a candidate in this patient because of the
frequent observation of multiple central nuclei in other
RYR1-related phenotypes and the suggestion of a clinical
continuum and overlap of radiological features on muscle
MRI. Functional studies on patient-derived, MyoD-trans-
formed fibroblasts indicated that cells harbouring this
mutation may be hypersensitive to depolarization, but it
remains unclear how the change gives rise to the appear-
ance of CNM. The frequency of the RYR1-related form of
CNM is currently uncertain.
Mutations in the amphiphysin-2 (BIN1) gene on chromo-
some 2q14 have been recently identified in a small pro-
portion of cases with the recessive form of centronuclear
myopathy [59] but further genetic heterogeneity is
expected. The BIN1 gene is organised in 20 exons, the pro-
tein exists in at least 10 different isoforms subject to alter-
native splicing and, in addition to muscle, the gene is
expressed in a number of different tissues including cen-
tral and peripheral nervous systems [134,135]. BIN1 was
considered a candidate for genetically unresolved forms of
CNM because of functional characteristics shared with
other CNM-associated genes, namely a phosphoinositide-
regulated role in membrane modelling [136], and the
presence of a muscle phenotype in the Drosophila mela-
nogaster mutant [137]. The amphiphysin 2 muscle-spe-
cific isoform features an N-terminal amphipathic helix
thought to be involved in creating membrane curvature, a
BAR (Bin1, Amphiphysin, RVS167) domain that
homodimerizes and maintains the curvature, a phosphoi-
nositide-binding domain, and an SH3 domain interacting
with dynamin 2 and other proteins [136,138]. Functional
studies on the three mutations identified to date suggest
that BIN1 missense mutations in the N-BAR domain affect
membrane curvature, whilst a truncating mutation in the
SH3 domain appears to abolish amphiphysin2-dynamin
2 interactions [59]; this indicates the importance of
amphiphysin 2-dynamin 2 coupling for normal muscle
function and suggests a possible alteration of T-tubule
organisation, as amphiphysin 2 was previously proposed
to have a role in this process [137,139].
In addition to the BIN1-related form, heterozygous mis-
sense variants in hJUMPY, a novel phosphoinositide
phosphatase with functional similarities to myotubularin,
were recently identified in two sporadic cases with fea-
tures of centronuclear myopathy and an additional
DNM2 mutation in one case [140]. These variants were
shown to decrease the enzymatic activity of hJUMPY in in
vitro and in cellulo experiments. It is unclear whether the
phenotype in those cases is due to digeny or recessive
inheritance with an undetected second mutation, and
clarification of the implication of hJUMPY awaits the
characterisation of additional patients with mutations in
this gene.
Genes implicated in various forms of centronuclear
myopathy have been summarised in Table 1.
Diagnostic methods
The diagnosis of CNM depends on the presence of typical
histopathological findings on muscle biopsy in combina-
tion with suggestive clinical features; muscle MR imaging
may complement clinical assessment and inform genetic
testing in cases with equivocal features.
On muscle biopsy, centronuclear (myotubular) myopa-
thy is characterised by centrally placed nuclei surrounded
by a perinuclear halo devoid of myofilaments [2] and
occupied by mitochondrial and glycogen aggregates (Fig-
ure 2) The characteristic central nuclei are seen in all mus-
cles, including extra-ocular muscles [141], and may affect
up to 90% of fibres [52]. Some autosomal cases of centro-
nuclear myopathy may also feature a radial arrangement
of sarcoplasmic strands on NADH staining [50]; it cur-
rently appears that this is a feature in most cases of centro-
nuclear myopathy caused by mutations in the DNM2
gene [76]: Whilst radial arrangement of sarcoplasmic
strands appears to be common in mild forms of DNM2-
related CNM due to mutations affecting the middle
domain [77], this finding appears not to be as prominentOrphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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in more severe and early presentations due to mutations
affecting the pleckstrin homology (PH) domain, or in
other genetically distinct forms of CNM. Type 1 predomi-
nance and hypotrophy [14,142] are commonly associated
features, and may precede the appearance of internal
nuclei [143]; there may be compensatory type 2 hypertro-
phy in a small number of fibres [25], and a deficiency of
type 2B fibres with relative increase in undifferentiated
type 2C fibres [142].
More recently, Pierson et al. [110] were able to correlate
MTM1 mutation type and pathologic findings and could
demonstrate that missense mutations are associated with
increased myofibre diameter compared to nonsense
mutations.
Histopathological changes may progress over time and
marked increases in fat [144] and connective tissue
[37,78,145] can at times be a striking feature. Associated
core-like structures have occasionally been reported
[47,144] and may be associated with mutations in both
the skeletal muscle ryanodine receptor (RYR1) gene [82]
and the DNM2 gene [78].
Reported histopathological findings in carriers of the X-
linked form range from normal appearance in clinically
asymptomatic mothers [11] to findings similar to those in
affected males, as reported in a female with the full clini-
cal picture of myotubular myopathy due to skewed X-
inactivation [37].
On electron microscopy (EM), immaturity of neuromus-
cular junctions and junctional changes comprising reduc-
tion of acetylcholine receptors on immunoperoxidase
stains [141] and simplification of the postsynaptic mem-
brane with paucity of secondary synaptic clefts [146] have
been reported but the molecular basis for this observation
remains uncertain. The great majority of CNM-related
electron microscopy studies either predate the molecular
resolution of these conditions or concern X-linked myotu-
bular myopathy, and there are currently not sufficient
data for more detailed EM genotype-phenotype correla-
tive studies with a view to the more recently identified
genes.
Immunohistochemical studies in CNM are mainly availa-
ble for the X-linked form and have demonstrated consist-
ent but non-specific abnormalities: persistent foetal
expression pattern of various proteins including the cell
surface protein N-CAM [146], myosin [32,147], vimentin
and desmin [145,148,149] have been reported in male
infants with the X-linked forms, but more recent immu-
nohistochemical studies on sequential biopsies in long-
term survivors [150] suggest that the expression of devel-
opmentally regulated proteins eventually decreases as in
healthy individuals. Other proteins abnormally expressed
in myotubular myopathy include laminin and collagen
components [145].
Muscle MRI findings have been reported in autosomal
forms of CNM due to mutations in the DNM2 [77,78] and
the RYR1 [82] genes. Muscle MRI in cases of centronuclear
Table 1: Genes implicated in X-linked recessive, autosomal-recessive and autosomal-dominant centronuclear myopathy.
Gene Gene product Locus Inheritance Reference
MTM1 Myotubularin Xq28 Recessive Laporte et al. (1996) [96]
DNM2 Dynamin 2 19p13.2 Autosomal-dominant Bitoun et al. (2005) [76]
RYR1* Skeletal muscle ryanodine receptor 19q13.1 Autosomal-dominant Jungbluth et al. (2007) [82]
BIN1 Amphiphysin 2 2q14 Autosomal-recessive Nicot et al. (2007) [59]
MTMR14** Myotubularin-related protein 14 (hJUMPY) 3p25.3 uncertain Tosch et al. (2006) [140]
*A mutation in the RYR1 gene has only been identified in one isolated case to date.
**Mutations in the MTMR14 gene have been identified in only two families with uncertain mode of inheritance.
Muscle biopsy from the quadriceps taken at 3 months of age  from a girl with X-linked centronuclear ("myotubular")  myopathy due to a mutation in the myotubularin (MTM1)  gene and extremely skewed X-inactivation, H&E stain, trans- verse section Figure 2
Muscle biopsy from the quadriceps taken at 3 
months of age from a girl with X-linked centronu-
clear ("myotubular") myopathy due to a mutation in 
the myotubularin (MTM1) gene and extremely 
skewed X-inactivation, H&E stain, transverse sec-
tion. Note marked variability in fibre size, moderate increase 
in connective tissue and numerous central nuclei.Orphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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myopathy secondary to mutations in the DNM2  gene
show a characteristic progressive sequence (Figure 3) with
early involvement of the ankle plantarflexors and subse-
quent signal changes within the hamstring muscles and,
finally, the anterior thigh. This sequence and also the
prominent adductor longus and rectus femoris involve-
ment reported in one family [78] is distinct from cases
with mutations in the RYR1 gene [82,151] and may guide
genetic testing in autosomal cases, particularly as cores on
oxidative stains may be an additional finding in both
DNM2- and RYR1-related forms [78,82]. Muscle imaging
findings in MTM1-related CNM have only been reported
in one manifesting female carrier [152] and are currently
not documented for the recessive form due to mutations
in the amphiphysin2 (BIN1) gene.
DNA sequencing of the exons and exon-intron bounda-
ries of the implicated genes is used to confirm the diagno-
sis at the molecular level. For MTM1  sequencing, it is
recommendable to start by investigating the more fre-
quently implicated exons although mutations have been
found distributed throughout the gene. With regard to
DNM2 mutation screening, mutations identified to data
are clearly concentrated in the middle and PH domains
and these hotspots should be checked first. Due to lack of
clear genotype-phenotype correlations and in cases where
the genetic segregation of the disease cannot be assessed
unambiguously, it is advisable to examine all three genes
(MTM1, BIN1 and DNM2) in the search for molecular
confirmation of the diagnosis.
RNA sequencing may be used if tissue or cultured cells are
available from the patient, as the implicated genes appear
to be ubiquitously expressed. For the X-linked form, the
vast majority of the known MTM1 mutations lead to a
decrease in protein levels in cultured myoblasts, fibrob-
lasts or lymphoblastoid cell lines [153]; based on only a
few cases studied, mutations in the BIN1 and DNM2 gene
do not seem to affect protein levels in such cell types. In
addition, investigation of the RNA integrity or protein lev-
els, although not used routinely, might reveal mutations
in introns or regulatory sequences that remain undetected
by DNA sequencing [100].
Differential diagnosis
Central nuclei on muscle biopsy are not pathognomonic,
and other neuromuscular disorders with a secondary
increase in internal nuclei have to be considered in the dif-
ferential diagnosis of CNM. Congenital myotonic dystro-
phy is a histopathological phenocopy [154] of the X-
linked form, myotubular myopathy, and ought to be con-
sidered and excluded in the first instance by obtaining a
detailed family history, clinical examination of the
mother and specific genetic testing as indicated, before
embarking on a muscle biopsy. In addition, although
often already unlikely on clinical grounds, other causes of
severe neonatal hypotonia ought occasionally to be
excluded by more specific testing, including the other con-
genital myopathies, the congenital muscular dystrophies,
spinal muscular atrophy, myasthenic disorders and motor
neuropathies.
The autosomal-dominant form of myotubular myopathy
[50,61-63,76] also has to be differentiated from myotonic
dystrophy and other autosomal-dominant disorders with
numerous central nuclei on muscle biopsy, particularly in
cases where mutations in the currently known CNM genes
have been excluded, as clinical findings such as cataracts
or electrical myotonia (i.e. myotonic bursts on needle
EMG) [155,156] suggest that some of the families
reported in the premolecular era were affected by myot-
Selective muscle involvement in a 59-year-old man (A, B, E,  F) and his 28-year-old daughter with centronuclear myopathy  (C, D, G, H) due to a mutation in the dynamin 2 (DNM2)  gene, muscle MRI, transverse, T1-weighted sections from the  proximal (A, C) and distal (B, D) thigh and the proximal (E,  G) and distal lower leg (F, H) Figure 3
Selective muscle involvement in a 59-year-old man 
(A, B, E, F) and his 28-year-old daughter with centro-
nuclear myopathy (C, D, G, H) due to a mutation in 
the dynamin 2 (DNM2) gene, muscle MRI, transverse, 
T1-weighted sections from the proximal (A, C) and 
distal (B, D) thigh and the proximal (E, G) and distal 
lower leg (F, H). In the thigh there is increased signal inten-
sity within the adductor longus (AL), semimembranosus 
(SM), rectus femoris (RF), biceps femoris (BF), and vastus 
intermedius (VI) muscles with relative sparing of the adduc-
tor magnus (AM), gracilis (G), sartorius (S), semitendinosus 
(ST), vastus lateralis (VL), and vastus medialis (VM) muscles. 
Within the lower leg, there is predominant involvement of 
the gastrocnemius (GA), soleus (SO) an tibialis anterior (TA) 
muscles with relative sparing of the peroneal group (PG). 
Muscle involvement, particularly within the thigh, is milder in 
the daughter compared to her father. The pattern is distinct 
from that reported in congenital myopathies associated with 
mutations in the skeletal muscle ryanodine (RYR1) gene. (Fig-
ure courtesy of Dr Carsten Boennemann and Dr Joachim 
Schessl, reproduced from Schessl et al., Neuromuscular Dis-
orders 2007; 17:28–32, with permission from Elsevier).Orphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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onic dystrophy rather than autosomal-dominant centro-
nuclear myopathy. A facioscapulohumeral distribution of
weakness in other families [45,75] should lead to consid-
eration of facioscapulohumeral muscular dystrophy in
the differential diagnosis of autosomal-dominant centro-
nuclear myopathy.
Management
No curative treatment is currently available for any form
of CNM and management is essentially supportive, based
on a multidisciplinary approach.
X-linked myotubular myopathy is the most severe form of
CNM and usually, but not invariably, follows a fatal
course over days and weeks. Occasionally, long-term sur-
vival has been reported but often depends on the degree
of respiratory intervention; a few male infants may be
more mildly affected from the outset with better long-
term prognosis [6,18,19,22,27-29]. The decision regard-
ing the duration of respiratory support is not an easy one,
but as no firm prognostic criteria have yet been estab-
lished [19], an at least initially proactive stance should be
taken and any respiratory management decision should
be made on an individual basis rather than on diagnosis
alone. The latter approach is particularly advisable in
cases with neonatal presentation where the X-linked form
has been excluded, as recently described patients with
recessive mutations in the amphiphysin 2 (BIN1) [59]
gene and dominant mutations in the dynamin 2 (DNM2)
gene [76] follow a milder course and may even improve
over time. Patients who survive beyond the neonatal
period without immediate ventilatory requirement will
need close monitoring of their respiratory function,
including polysomnography studies where needed, and
are likely to benefit from initiation of non-invasive noc-
turnal ventilation as indicated [157]. Follow-up care of
those on nighttime ventilation should include regular car-
diac assessments considering the risk of associated cor
pulmonale [158,159]. Respiratory infections should be
treated actively.
Feeding difficulties usually feature in infants with X-
linked myotubular myopathy and may occur also in
patients with severe recessive and dominant forms of
CNM, requiring input from a speech therapist who may
also promote normal speech if dysarthria is present.
As in other congenital myopathies, regular physiotherapy
is aimed at the preservation of muscle power and function
and the prevention of contractures; considering often
prominent axial involvement, exercises promoting endur-
ance and truncal stability such as swimming and riding
[160] may be particularly useful. If orthopaedic complica-
tions evolve in the course of the disease, those may be
managed surgically where conservative approaches have
failed, and only at centres with experience in the manage-
ment of neuromuscular disorders. As in other neuromus-
cular conditions, post-operative mobilisation ought to be
rapid in order to avoid adverse effects of prolonged immo-
bilisation such as muscle atrophy. In the most severe cases
where walking can not be achieved without additional
support, independent ambulation may be promoted by
appropriate rehabilitative measures such as provision of
weight-bearing calipers.
Malignant hyperthermia, an abnormal response to muscle
relaxants such as succinylcholine and volatile anaesthetics
[161,162], has been previously only reported in one
genetically unresolved case of CNM [85] and may reflect
the recently documented involvement of the RYR1 gene in
the condition [82]. As malignant hyperthermia is not a
recognised feature of other genetically determined forms
of CNM, this complication ought to be mainly anticipated
in genetically unresolved cases or those due to RYR1
mutations, although a cautious approach is generally
advisable for patients with muscle disorders considered
for general anaesthesia.
Genetic counselling
Genetic counselling should be offered to all patients and
families in whom a diagnosis of CNM has been made.
Only the identification of the causative mutation will
determine the mode of inheritance in each individual
family. In families with mutations in the myotubularin
gene (MTM1), it is important to note that some women,
who do not show in their lymphocyte-derived DNA the
mutation identified in their affected son, may still carry a
risk of recurrence because of germinal mosaicism for the
mutation [97,108,109]. Mutational analysis of MTM1 is
now available as a diagnostic service, and in future the
same might apply to screening of the more recently iden-
tified dynamin 2 (DNM2)  and amphiphysin 2 (BIN1)
genes associated with dominant and recessive forms of
CNM, currently mainly available on a research basis. Con-
sidering the possible important prognostic implications
depending on the underlying genetic defect, there is
clearly a need for the establishment of a wider diagnostic
network for CNM.
Prognosis
The prognosis of CNM is vaguely related to the mode of
inheritance (see paragraph on Clinical description) with
the X-linked form being more severe than dominant or
recessive forms, respectively; whilst the mortality of X-
linked myotubular myopathy is very high in infancy,
some rare cases who are usually milder from the outset
may achieve a reasonable quality of life [27,28].
As only few genetically resolved families with dominant
and recessive forms of CNM due to mutations in theOrphanet Journal of Rare Diseases 2008, 3:26 http://www.ojrd.com/content/3/1/26
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DNM2 and BIN1 genes have been reported to date, geno-
type-phenotype correlations are still emerging (See para-
graph on Clinical description).
Unresolved questions
Whilst the genetic basis of the X-linked form of CNM
("myotubular myopathy") has been known for a long
time, recent years have seen the genetic resolution of a
proportion of the autosomal-dominant and the auto-
somal-recessive forms of the condition. Despite these
genetic advances, a substantial proportion of CNM cases
remain currently still genetically unresolved, suggesting
the existence of further gene loci. The pathological mech-
anisms leading to the skeletal muscle defects are still not
understood and, although abnormal positioning of the
nuclei is the histopathological hallmark of all genetically
defined forms of CNM, the link between the mutated pro-
teins and abnormal nuclear positioning remains
unknown. Finally, considering that those concern ubiqui-
tously expressed proteins, the tissue-specific expression of
some of the implicated CNM mutations remains unac-
counted for. Animal models may provide the basis for an
advanced understanding of CNM and for future rational
therapies of the condition.
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